Contact a LawyerSubmit information about your potential case to be reviewed by an attorney.
Published: October 1st, 2010
Reglan side effects have been associated with the development of tardive dyskinesia, a syndrome that causes involuntary movements in the body extremities, particularly the lower face. In February 2009, the FDA required that a “black box” warning about the tardive dyskinesia problems be added to Reglan and other gastrointestinal drugs containing metoclopramide.
REGLAN LAWSUIT STATUS: Lawyers are reviewing potential claims for individuals who may be entitled to compensation through a Reglan lawsuit as a result of developing tardive dyskinesia. The Reglan statute of limitations in many states may be approaching, so it is important to review what legal rights may be available as soon as possible.
- Reglan Tablets
- Reglan Oral Disintegrating Tablets
- Metoclopramide Oral Solution
- Reglan Injection
OVERVIEW: Reglan is used for treatment of gastrointestinal disorders. It contains metoclopramide, which works by increasing the movement of stomach muscles, speeding up the rate at which the stomach empties into the intestines.
When metoclopramide-containing drugs are used at high doses or for extended periods of time, it can increase the risk of developing tardive dyskinesia, which is associated with involuntary movements, such as:
- Movements in the Body Extremeties
- Lip Smacking
- Repetitive Chewing
- Pursing and Puckering of the Lips
- Tongue Protrusion
- Rapid Eye Movements and Blinking
- Impaired Finger Movements
TARDIVE DYSKINESIA SIDE EFFECTS: Reglan tardive dyskinesia side effects are more likely to occur with long-term use of the drug, use at high doses and among the elderly, especially women.
It is not recommended that metoclopramide-containing drugs like Reglan be used for more than three years due to the risk of Reglan side effects.
In February 2009, the FDA announced that they were requiring that a “black box” warning about the tardive dyskinesia side effects be added to the labels for all drugs containing metoclopramide. The drug makers will also be required to implement a risk evaluation and mitigation strategy to make sure that patients who receive these drugs in the future are fully informed about the risk of developing the side effects.